Gavriella Mavrikiou

Gavriella Mavrikiou

Auto-generated profile, based on publicly available information

Gavriella Mavrikiou

Biochemical Genetics Department The Cyprus Institute of Neurology and Genetics Nicosia Cyprus

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
AMAnna Malekkou
Anna Malekkou
ISIoanna Sevastou
Ioanna Sevastou
GMGavriella Mavrikiou
Gavriella Mavrikiou
TGTheodoros Georgiou
Theodoros Georgiou
LVLluisa Vilageliu
Lluisa Vilageliu
ADAnthi Drousiotou
Anthi Drousiotou
Background: Mutations in the GBA gene that encodes the lysosomal enzyme acid β‐glucocerebrosidase cause Gaucher disease (GD), the most common lysosomal storage disorder. Most of the mutations are missense/nonsense, however, a few splicing mutations within or close to conserved consensus donor or acceptor splice sites have also been described. The aim of the study was to identify the mutation(s) in a Cypriot patient with type I GD.Methods: The genomic DNA of the proband was screened for nine common mutations using Polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) analysis. All exons and exon‐intron boundaries, and the 5’UTR and 3’UTR regions of the GBA gene, were investigated by Sanger sequencing. RNA analysis was performed using standard procedures, and the abnormal transcript was further cloned into pGEM‐T‐Easy plasmid vector and sequenced. The relevant intronic region was further sequenced by the Sanger method to identify the genetic variant.Results: A novel point mutation, g.12599C > A (c.999 + 242C > A), was detected deep in intron 7 of the GBA gene. This type of mutation has been previously described for other diseases but this is the first time, as far as we know, that it is described for GD. This mutation creates a new donor splice site leading to aberrant splicing and resulting in the insertion of the first 239nt of intron 7 as a pseudoexon in the mRNA, creating a premature stop codon.Conclusion: This study expands the mutation spectrum of GD and highlights the importance of RNA sequencing for the molecular diagnosis of patients bearing mutations in nonexonic regions.

25 March 2024 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
AMAnna Malekkou
Anna Malekkou
MTMarios Tomazou
Marios Tomazou
GMGavriella Mavrikiou
Gavriella Mavrikiou
MDMaria Dionysiou
Maria Dionysiou
TGTheodoros Georgiou
Theodoros Georgiou
PPPetros Petrou
Petros Petrou
Background: Dihydropyrimidine dehydrogenase (DPD), is the initial and rate-limiting enzyme in the catabolic pathway of pyrimidines. Deleterious variants in the DPYD gene cause DPD deficiency, a rare autosomal recessive disorder. The clinical spectrum of affected individuals is wide ranging from asymptomatic to severely affected patients presenting with intellectual disability, motor retardation, developmental delay and seizures. DPD is also important as the main enzyme in the catabolism of 5-fluorouracil (5-FU) which is extensively used as a chemotherapeutic agent. Even in the absence of clinical symptoms, individuals with either complete or partial DPD deficiency face a high risk of severe and even fatal fluoropyrimidine-associated toxicity. The identification of causative genetic variants in DPYD is therefore gaining increasing attention due to their potential use as predictive markers of fluoropyrimidine toxicity. Methods: A male infant patient displaying biochemical features of DPD deficiency was investigated by clinical exome sequencing. Bioinformatics tools were used for data analysis and results were confirmed by MLPA and Sanger sequencing. Results: A novel intragenic deletion of 71.2 kb in the DPYD gene was identified in homozygosity. The deletion, DPYD(NM_000110.4):c.850 + 23455_1128 + 8811del, eliminates exons 9 and 10 and may have resulted from a non-homologous end-joining event, as suggested by in silico analysis. Conclusions: The study expands the spectrum of DPYD variants associated with DPD deficiency. Furthermore, it raises the concern that patients at risk for fluoropyrimidine toxicity due to DPYD deletions could be missed during pre-treatment genetic testing for the currently recommended single nucleotide polymorphisms.

21 April 2025 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
ADAnthi Demetriadou
Anthi Demetriadou
OGOlga Grafakou
Olga Grafakou
TGTheodoros Georgiou
Theodoros Georgiou
DBDaniela Burska
Daniela Burska
AMAnna Malekkou
Anna Malekkou
PPPetros Petrou
Petros Petrou
3‐methylglutaconic aciduria (3‐MGCA) is a biochemical finding in a diverse group of inherited metabolic disorders. Conditions manifesting 3‐MGCA are classified into two major categories, primary and secondary. Primary 3‐MGCAs involve two inherited enzymatic deficiencies affecting leucine catabolism, whereas secondary 3‐MGCAs comprise a larger heterogeneous group of conditions that have in common compromised mitochondrial energy metabolism. Here, we report 3‐MGCA in two siblings presenting with sensorineural hearing loss and neurological abnormalities associated with a novel, homozygous missense variant (c.1999C>G, p.Leu667Val) in the YME1L1 gene which encodes a mitochondrial ATP‐dependent metalloprotease. We show that the identified variant results in compromised YME1L1 function, as evidenced by abnormal proteolytic processing of substrate proteins, such as OPA1 and PRELID1. Consistent with the aberrant processing of the mitochondrial fusion protein OPA1, we demonstrate enhanced mitochondrial fission and fragmentation of the mitochondrial network in patient‐derived fibroblasts. Furthermore, our results indicate that YME1L1 L667V is associated with attenuated activity of rate‐limiting Krebs cycle enzymes and reduced mitochondrial respiration, which may explain the build‐up of 3‐methylglutaconic and 3‐methylglutaric acid due to the diversion of acetyl‐CoA, not efficiently processed in the Krebs cycle, towards the formation of 3‐methylglutaconyl‐CoA, the precursor of these metabolites. In summary, our findings classify YME1L1 deficiency as a new type of secondary 3‐MGCA, thus expanding the genetic landscape and facilitating the diagnosis of inherited metabolic disorders featuring this biochemical phenotype.